Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1244

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Enzalutamide
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC